Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Neoplasms 1

Interventions

Carboplatin 283Cisplatin 225Pemetrexed 196Paclitaxel 151Docetaxel 132pembrolizumab 109Gemcitabine 94Etoposide 64Erlotinib Hydrochloride 59Radiotherapy 54Vinorelbine 47durvalumab 46Gefitinib 46Bevacizumab 46atezolizumab 42Nivolumab 40Drug Therapy 34osimertinib 30Topotecan 29tislelizumab 23130-nm albumin-bound paclitaxel 23Radiosurgery 21Ipilimumab 18Crizotinib 18Magnetic Resonance Spectroscopy 15Albumin-Bound Paclitaxel 15Surgical Procedures, Operative 14aumolertinib 13Platinum 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × motesanib diphosphate × Thoracic × Clear all
NCT02629848 2015-12-14

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Takeda

Phase 3 Terminated
401 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00460317 2015-09-07

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Amgen

Phase 3 Terminated
1,450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡